These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 35180650)

  • 1. The prognostic impact of Claudin 6 in papillary renal cell carcinoma.
    Mikuteit M; Zschäbitz S; Stöhr C; Herrmann E; Polifka I; Agaimy A; Trojan L; Ströbel P; Becker F; Wülfing C; Barth P; Stöckle M; Staehler M; Stief C; Haferkamp A; Hohenfellner M; Macher-Göppinger S; Wullich B; Noldus J; Brenner W; Roos FC; Walter B; Otto W; Burger M; Schrader AJ; Hartmann A; Steffens S; Erlmeier F
    Pathol Res Pract; 2022 Mar; 231():153802. PubMed ID: 35180650
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Prognostic Impact of PD-L2 in Papillary Renal-Cell Carcinoma.
    Mondorf Y; Mikuteit M; Ivanyi P; Stöhr C; Herrmann E; Polifka I; Agaimy A; Trojan L; Ströbel P; Becker F; Wülfing C; Barth P; Stöckle M; Staehler M; Stief CG; Haferkamp A; Hohenfellner M; Macher-Göppinger S; Wullich B; Noldus J; Brenner W; Roos FC; Walter B; Otto W; Burger M; Schrader AJ; Hartmann A; Steffens S; Erlmeier F
    Urol Int; 2022; 106(11):1168-1176. PubMed ID: 35654002
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of Gas 6 as a Prognostic Marker in Papillary Renal Cell Carcinoma.
    Mikuteit M; Zschäbitz S; Stöhr C; Herrmann E; Polifka I; Agaimy A; Trojan L; Ströbel P; Becker F; Wülfing C; Barth P; Stöckle M; Staehler M; Stief C; Haferkamp A; Hohenfellner M; Duensing S; Macher-Göppinger S; Wullich B; Noldus J; Brenner W; Roos F; Walter B; Otto W; Burger M; Erlmeier M; Schrader AJ; Hartmann A; Erlmeier F; Steffens S;
    Urol Int; 2023; 107(7):713-722. PubMed ID: 37348477
    [TBL] [Abstract][Full Text] [Related]  

  • 4. cMET: a prognostic marker in papillary renal cell carcinoma?
    Erlmeier F; Bruecher B; Stöhr C; Herrmann E; Polifka I; Agaimy A; Trojan L; Ströbel P; Becker F; Wülfing C; Barth P; Stöckle M; Staehler M; Stief C; Haferkamp A; Hohenfellner M; Macher-Göppinger S; Wullich B; Noldus J; Brenner W; Roos FC; Walter B; Otto W; Burger M; Schrader AJ; Hartmann A; Mondorf Y; Ivanyi P; Mikuteit M; Steffens S;
    Hum Pathol; 2022 Mar; 121():1-10. PubMed ID: 34998840
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of PD-1 and PD-L1 Expression in Papillary Renal Cell Carcinoma: Results of a Large Multicenter Study.
    Erlmeier F; Steffens S; Stöhr C; Herrmann E; Polifka I; Agaimy A; Trojan L; Ströbel P; Becker F; Wülfing C; Barth P; Stöckle M; Staehler M; Stief C; Haferkamp A; Hohenfellner M; Macher-Göppinger S; Wullich B; Noldus J; Brenner W; Roos FC; Walter B; Otto W; Burger M; Schrader AJ; Hartmann A; Ivanyi P;
    Clin Genitourin Cancer; 2021 Feb; 19(1):53-59.e1. PubMed ID: 32778505
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Claudins as prognostic factors for renal cell cancer.
    Virman J; Soini Y; Kujala P; Luukkaala T; Salminen T; Sunela K; Kellokumpu-Lehtinen PL
    Anticancer Res; 2014 Aug; 34(8):4181-7. PubMed ID: 25075044
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression patterns of claudins 1, 4, and 7 and their prognostic significance in nasopharyngeal carcinoma.
    Suren D; Yildirim M; Kaya V; Elal R; Selcuk OT; Osma U; Yildiz M; Gunduz S; Sezer C
    J BUON; 2015; 20(1):212-7. PubMed ID: 25778318
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Claudins 10 and 18 are predominantly expressed in lung adenocarcinomas and in tumors of nonsmokers.
    Merikallio H; Pääkkö P; Harju T; Soini Y
    Int J Clin Exp Pathol; 2011; 4(7):667-73. PubMed ID: 22076167
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Claudin-7 immunohistochemistry in renal tumors: a candidate marker for chromophobe renal cell carcinoma identified by gene expression profiling.
    Hornsby CD; Cohen C; Amin MB; Picken MM; Lawson D; Yin-Goen Q; Young AN
    Arch Pathol Lab Med; 2007 Oct; 131(10):1541-6. PubMed ID: 17922590
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of claudins-1, -4, -5, -7 and occludin in hepatocellular carcinoma and their relation with classic clinicopathological features and patients' survival.
    Bouchagier KA; Assimakopoulos SF; Karavias DD; Maroulis I; Tzelepi V; Kalofonos H; Karavias DD; Kardamakis D; Scopa CD; Tsamandas AC
    In Vivo; 2014; 28(3):315-26. PubMed ID: 24815833
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence and prognostic value of FBXO11 expression in patients with clear cell renal cell carcinoma.
    Fan B; Wang W; Zhang X; Sun M; Wang X; Chen Z; Liu W; Wang Q; Yu N; Li X
    BMC Cancer; 2019 Jun; 19(1):534. PubMed ID: 31159774
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinicopathological, genetic, ultrastructural characterizations and prognostic factors of papillary renal cell carcinoma: new diagnostic and prognostic information.
    Yu W; Zhang W; Jiang Y; Wang Y; Li Y; Wang J; Sun L; Ran W; Li H
    Acta Histochem; 2013 Jun; 115(5):452-9. PubMed ID: 23219441
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Type II papillary histology predicts poor outcome in patients with renal cell carcinoma and vena cava thrombus.
    Kim KH; You D; Jeong IG; Kwon TW; Cho YM; Hong JH; Ahn H; Kim CS
    BJU Int; 2012 Dec; 110(11 Pt B):E673-8. PubMed ID: 22973869
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High CENPA expression in papillary renal cell carcinoma tissues is associated with poor prognosis.
    Li J; Li Q; Yuan Y; Xie Y; Zhang Y; Zhang R
    BMC Urol; 2022 Sep; 22(1):157. PubMed ID: 36163007
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FGFR2 overexpression predicts survival outcome in patients with metastatic papillary renal cell carcinoma.
    Tsimafeyeu I; Khasanova A; Stepanova E; Gordiev M; Khochenkov D; Naumova A; Varlamov I; Snegovoy A; Demidov L
    Clin Transl Oncol; 2017 Feb; 19(2):265-268. PubMed ID: 27379982
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Three-gene risk model in papillary renal cell carcinoma: a robust likelihood-based survival analysis.
    Wang Y; Yan K; Lin J; Wang J; Zheng Z; Li X; Hua Z; Bu Y; Shi J; Sun S; Li X; Liu Y; Bi J
    Aging (Albany NY); 2020 Nov; 12(21):21854-21873. PubMed ID: 33154194
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnostic and prognostic tissuemarkers in clear cell and papillary renal cell carcinoma.
    Kroeze SG; Bijenhof AM; Bosch JL; Jans JJ
    Cancer Biomark; 2010; 7(6):261-8. PubMed ID: 21694464
    [TBL] [Abstract][Full Text] [Related]  

  • 18. GCN2 is a potential prognostic biomarker for human papillary renal cell carcinoma.
    Ge L; Chen W; Cao W; Liu G; Zhang Q; Zhuang J; Zhang M; Yang J; Guo S; Zhao X; Guo H
    Cancer Biomark; 2018; 22(3):395-403. PubMed ID: 29865032
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A pan-cancer perspective analysis reveals the opposite prognostic significance of CD133 in lower grade glioma and papillary renal cell carcinoma.
    Wang H; Wang X; Xu L; Zhang J; Cao H
    Sci Prog; 2021; 104(2):368504211010938. PubMed ID: 33878963
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Integrated Phenotypic/Genotypic Analysis of Papillary Renal Cell Carcinoma Subtypes: Identification of Prognostic Markers, Cancer-related Pathways, and Implications for Therapy.
    Saleeb RM; Plant P; Tawedrous E; Krizova A; Brimo F; Evans AJ; Wala SJ; Bartlett J; Ding Q; Boles D; Rotando F; Farag M; Yousef GM
    Eur Urol Focus; 2018 Sep; 4(5):740-748. PubMed ID: 28753789
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.